SCHEMBL3886308

SCHEMBL3886308

O=C(O)Nc1nccc2c1ccn2-c1ccc(NC(=S)NC(=O)Cc2ccc(F)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 5/20 0.48
▸ AXL P30530 1/20 0.48
▸ TP53 P04637 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ ALDH1A1 P00352 5/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ GAA P10253 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ RAB9A P51151 1/20 0.39
▸ KDR P35968 2/20 0.39
▸ FLT1 P17948 1/20 0.39
▸ FLT4 P35916 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13759619 0.88 MET (0.45) METAXLTP53THRBALDH1A1
SCHEMBL3885800 0.88 MET (0.49) METAXLTP53THRBALDH1A1
SCHEMBL3882961 0.84 TP53 (0.48) METTP53THRBALDH1A1MEN1
SCHEMBL5317938 0.80 TP53 (0.45) TP53THRBALDH1A1MEN1GAA
SCHEMBL3883270 0.79 MET (0.49) METTP53THRBGAASMN1; SMN2
SCHEMBL14096629 0.72 RAB9A (0.69) ALDH1A1MEN1GAAKMT2AMAPT
SCHEMBL13759627 0.71 MET (0.41) METTP53THRBMAPTPDGFRA
SCHEMBL5313559 0.71 TP53 (0.45) METAXLTP53THRBALDH1A1
SCHEMBL3879873 0.71 CSF1R (0.36) TP53KDR
SCHEMBL4070432 0.71 GAA (0.62) METAXLALDH1A1MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566784-B2 Bicyclic heterocycles as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-07-28 — — US disclosed
EP-1742948-A2 BICYCLIC HETEROCYCLES AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-01-17 — — EP disclosed
WO-2005116028-A2 BICYCLIC HETEROCYCLES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-08 — — WO disclosed
US-20050239820-A1 Bicyclic heterocycles as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239820-A1 Bicyclic heterocycles as kinase inhibitors CDK2, ABL1, CDKN1A MET 610/4885AXL 368/4885TP53 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback